郭旭

• 1:鞍山市鞍钢总医院心内科

摘要(Abstract)：

主动脉瓣狭窄是老年患者中常见的瓣膜病变,传统外科手术对高龄、术前合并其他疾病的患者可能导致严重的并发症。经导管主动脉瓣置换术(TAVR)自2002年首次应用于人体以来,因其创伤小、恢复快等优点,手术比例逐年升高,逐渐发展为治疗中危患者的外科主动脉瓣置换术的替代方案。我国自2010年开展TAVR,经过十年的发展,呈现出开展单位迅猛增多、器械研发如火如荼的态势。本文从TAVR的产生、现状、面临的挑战及瓣膜的进展方面作一综述。

关键词(KeyWords)： 经导管主动脉瓣置换术;主动脉瓣狭窄;人工;心脏瓣膜

Abstract:

Keywords:

基金项目(Foundation):

作者(Author): 郭旭

参考文献(References)：

• [1]Zakkar M,Bryan AJ,Angelini GD.Aortic stenosis:diagnosis and management.BMJ,2016,355:i5425.
• [2]Kanwar A,Thaden JJ,Nkomo VT.Management of patients with aortic valve stenosis.Mayo Clin Proc,2018,93(4):488-508.
• [3]Nkomo VT,Gardin JM,Skelton TN,et al.Burden of valvular heart diseases:a population based study.Lancet,2006,368(9540):1005-1011.
• [4]Green P,Cohen DJ,Généreux P,et al.Relation between sixminute walk test performance and outcomes after transcatheter aortic valve implantation (from the PARTNER trial).Am JCardiol,2013,112(5):700-706.
• [5]Saxena A,Poh CL,Dinh DT,et al.Early and late outcomes after isolated aortic valve replacement in octogenarians:an Australasian Society of Cardiac and Thoracic Surgeons Cardiac Surgery Database Study.Eur J Cardiothorac Surg,2012,41(1):63-68.
• [6]Cribier A.The development of transcatheter aortic valve replacement(TAVR).Glob Cardiol Sci Pract,2016,2016(4):e201632.
• [7]Cribier A,Ehchaninoff H,Bash A,et al.Percutaneous transcatheter implantation of an aortic valve prosthesis for calcific aortic stenosis:first human case description.Circulation,2002,106(24):3006-3008.
• [8]Stortecky S,Franzone A,Heg D,et al.Temporaltrends in adoption and outcomes of transcatheter aortic valve implantation:a Swiss TAVR Registry analysis.Eur Heart J Qual Care Clin Outcomes,2019,5(3):242-251.
• [9]Di Mario C,Eltchaninoff H,Moat N,et al.The 2011-12 pilot European Sentinel Registry of transcatheter aortic valve implantation:in-hospital results in 4,571 patients.Euro Intervention,2013,8(12):1362-1371.
• [10]Mylotte D,Osnabrugge RLJ,Windecker S,et al.Transcatheter aortic valve replacement in Europe:adoption trends and factors influencing device utilization.J Am Coll Cardiol,2013,62(3):210-219.
• [11]Nishimura RA,Otto CM,Bonow RO,et al.2017 AHA/ACC focused update of the 2014 AHA/ACC Guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.J Am Coll Cardiol,2017,70(2):252-289.
• [12]Baumgartner H,Falk V,Bax JJ,et al.2017 ESC/EACTSGuidelines for the management of valvular heart disease.Eur Heart J,2017,38(36):2739-2791.
• [13]国家心血管病专家委员会微创心血管外科专业委员会.中国经导管主动脉瓣置入术（TAVR）多学科专家共识.中华胸心血管外科杂志，2018,34(12):705-712.
• [14]Nishimura RA,Otto CM,Bonow RO,et al.2014AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association task force on practice guidelines.J Thorac Cardiovasc Surg,2014,148(1):e1-e132.
• [15]Thourani VH,Edelman JJ,Meduri CU.TAVR in TAVR:the future is now.J Am Coll Cardiol,2020,75(16):1894-1896.
• [16]Mack M,Leon BM,Thourani V,et al.Transcatheter aorticvalve replacement with a balloon-expandable valve in low-risk patients.N Engl J Med,2019,380(18):1695-1705.
• [17]中国医师协会心血管内科医师分会结构性心脏病专业委员会.经导管主动脉瓣置换术中国专家共识（2020更新版）.中国介入心脏病学杂志，2020,28(6):301-309.
• [18]Erkapic D,De Rosa S,Kelava A.Risk for permanent pacemaker after transcatheter aortic valve implantation:a comprehensive analysis of the literature.J Cardiovasc Electrophysiol,2012,23(4):391-397.
• [19]Siontis GC,Jüni P,Pilgrim T,et al.Predictors of permanent pacemaker implantation in patients with severe aortic stenosis undergoing TAVR.J Am Coll Cardiol,2014,64(2):129-140.
• [20]Mas-Peiro S,Fichtlscherer S,Walther C,et al.Current issues in transcatheter aortic valve replacement.J Thorac Dis,2020,12(4):1665-1680.
• [21]Van Belle E,Juthier F,Susen S,et al.Postprocedural aortic regurgitation in balloon-expandable and self-expandable transcatheter aortic valve replacement procedures:analysis of predictors and impact on long-term mortality:insights from the FRANCE2 Registry.Circulation,2014,129(13):1415-1427.
• [22]Kodali S,Pibarot P,Douglas PS,et al.Paravalvular regurgitation after transcatheter aortic valve replacement with the Edwards sapien valve in the PARTNER trial:characterizing patients and impact on outcomes.Eur Heart J,2015,36(7):449-456.
• [23]Dworakowski R,Wendler O,Halliday B,et al.Device-dependent association between paravalvar aortic regurgitation and outcome after TAVR.Heart,2014,100(24):1939-1945.
• [24]Athappan G,Patvardhan E,Tuzcu EM,et al.Incidence,predictors,and outcomes of aortic regurgitation after transcatheter aortic valve replacement:meta-analysis and systematic review of literature.J Am Coll Cardiol,2013,61(15):1585-1595.
• [25]Mack MJ,Leon MB,Smith CR,et al.5-year outcomes of transcatheter aortic valve replacement or surgical aortic valve replacement for high surgical risk patients with aortic stenosis(PARTNER 1):a randomised controlled trial.Lancet,2015,385(9986):2477-2484.
• [26]Kachel M,Milewski K,Buszman P,et al.State-of-the-art of transcatheter treatment of aortic valve stenosis and the overview of the In Flow project aiming at developing the first Polish TAVR system.Cardiol J,2017,24(6):685-694.
• [27]Nishimura RA,Otto CM,Bonow RO,et al.2017 AHA/ACC focused update of the 2014 AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association task force on clinical practice guidelines.Circulation,2017,135(25):e1159-e1195.
• [28]Nishimura RA,Otto CM,Bonow RO,et al.2014AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association Task force on practice guidelines.Circulation,2014,129 (23):e521-e643.
• [29]Barbanti M,Webb JG,Tamburino C,et al.Outcomes of redo transcatheter aortic valve replacement for the treatment of postprocedural and late occurrence of paravalvular regurgitation and transcatheter valve failure.Circ Cardiovasc Interv,2016,9(9):e003930.
• [30]Douglas PS,Leon MB,Mack MJ,et al.Longitudinal hemodynamics of transcatheter and surgical aortic valves in the PARTNER trial.JAMA Cardiol,2017,2(11):1197-1206.
• [31]Hecker F,Arsalan M,Kim WK.Transcatheter aortic valve implantation (TAVR) in 2018:recent advances and future development.Minerva Cardioangiol,2018,66(3):314-328.
• [32]Tommaso CL,Bolman RM,Feldman T,et al.Multisociety(AATS,ACCF,SCAI,and STS) expert consensus statement:operator and institutional requirements for transcatheter valve repair and replacement,Part 1:transcatheter aortic valve replacement.J Thorac Cardiovasc Surg,2012,143(6):1254-1263.
• [33]Solomonica A,Choudhury T,Bagur R.Newer-generation of Edwards transcatheter aortic Valve systems:SAPIEN 3,Centera,and SAPIEN3 Ultra.Expert Rev Med Devices,2019,16(2):81-87.
• [34]Nishimura RA,Otto CM,Bonow RO,et al.2014AHA/ACC guideline for the management of patients with valvular heart disease:a report of the American College of Cardiology/American Heart Association task force on practice guidelines.J Am Coll Cardiol,2014,63(22):e57-e185.
• [35]Sch?fer U,Schirmer J,Niklas S,et al.First-in-human implantation of a novel transfemoral self-expanding transcatheter heart Valve to treat pure aortic regurgitation.Euro Intervention,2017,13(11):1296-1299.